Bitcoin hits record high over $124k on rate cut bets, corporate treasury cheer
BOSTON - Ironwood Pharmaceuticals , Inc. (NASDAQ:IRWD) saw its stock jump 9.4% after reporting fourth quarter earnings and providing updates on its pipeline drug apraglutide for short bowel syndrome.
The biotechnology company reported fourth quarter adjusted earnings per share of $0.02, missing analyst estimates of $0.06. Revenue came in at $90.55 million, below the consensus of $92.5 million.
Despite the earnings miss, investors focused on positive developments for apraglutide. Ironwood initiated a rolling New Drug Application submission to the FDA, with completion expected in Q3 2025. The company also announced encouraging data from an open-label extension study showing more patients weaning off parenteral support over time with apraglutide treatment.
"We have initiated the rolling NDA submission for apraglutide, and we are working with urgency to complete the submission and prepare for potential launch," said CEO Tom McCourt.
For its marketed drug Linzess, Ironwood reported 11% year-over-year prescription demand growth for full-year 2024. However, U.S. net sales of Linzess declined 15% to $916.3 million for 2024 compared to 2023.
Looking ahead, Ironwood provided 2025 revenue guidance of $260-290 million, compared to analyst expectations of $287.6 million. The company expects Linzess U.S. net sales of $800-850 million in 2025.
Ironwood ended 2024 with $88.6 million in cash and cash equivalents. The company generated $103.5 million in cash from operations for the full year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.